---
title: "Developing the undevelopable with Dave Miller, Chief Science Officer at AustinPx"
canonical: "https://www.qualio.com/podcasts/developing-the-undevelopable-with-dave-miller-chief-science-officer-at-austinpx"
pubDate: "2025-07-01T15:00:00.000Z"
updatedDate: "2026-09-10T15:33:34.000Z"
description: ""
---

As complexity in pharmaceutical development reaches new heights — especially with over 60% of recent FDA novel molecular entities falling outside traditional drug design rules — the need for advanced formulation and manufacturing strategies has never been greater. Precision medicine is no longer a future goal; it’s a present necessity. And that’s exactly where AustinPx comes in.

At the forefront of this shift is AustinPx’s KinetiSol technology, a powerful platform designed to make the “undevelopable” developable — transforming poorly soluble, highly potent small molecules into scalable, patient-ready therapies.

Dr. Dave Miller, CSO, has spent more than 20 years in pharmaceutical R&D, helping drug developers navigate the challenges of bioavailability, permeability, and manufacturability for complex molecules.

Today, we’ll explore with Dave how CDMOs like AustinPx are empowering a new era of personalized treatment—while offering product protection strategies that help biopharma companies stand out in a competitive, cost-sensitive market.

Qualio website:  
https://www.qualio.com/

Previous episodes:  
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:  
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez